PrimeVax Immuno-Oncology

PrimeVax Immuno-Oncology

PrimeVax Immuno-Oncology is a biotechnology company developing one-time one-week cancer treatments.

PrimeVax Immuno-Oncology is a biotechnology company developing one-time one-week cancer treatments that is headquartered in Orange, California and was founded in 2015 by Boris Minev and Santosh Kesari.

PrimeVax Immuno-Oncology is a interested in creating treatments for cancer that utilize the entire body and personalized neo-antigens. The company worked with the combination of the dengue fever virus and autologous dendritic cells in order to create and induce a strong immune response with personalized tumor targeting. This process is part of their one-time, one-week cancer treatment.

The dengue virus is used to activate the body's natural immune functions, and the strain that is used has a zero mortality rate. The strain has also been shown to have a tolerable event profile. The autologous dendritic cells are used to direct the activated immune system to attack the patient's tumors. They are derived from the patient's native white blood cells and tumor cells to teach the T-cells the antigenic information regarding the patient's own tumors.

Timeline

January 22, 2019

PrimeVax Immuno-Oncology, Inc. announced an exclusive, worldwide license with the US Army Medical Materials Development Activity authorizing PrimeVax to use dengue virus-1 #45AZ5 strain for treatment of cancer

People

Name
Role
LinkedIn

Boris Minev

Science Co-Founder

Bruce Lyday

CTO

Santosh Kesari

Science Co-Founder

Tony Chen

CEO

Further reading

Title
Author
Link
Type
Date

PrimeVax Immuno-Oncology Signs Exclusive Worldwide Dengue Virus License with US Army for Cancer Treatments

PrimeVax Immuno-Oncology

Web

PrimeVax Immuno-Oncology, Inc.

Web

Technology | primevax

Web

Documentaries, videos and podcasts

Title
Date
Link

Companies

Company
CEO
Location
Products/Services

PrimeVax Immuno-Oncology

Tony Chen

Orange, California, United States

Cancer Treatments

References

Golden logo
Text is available under the Creative Commons Attribution-ShareAlike 4.0; additional terms apply. By using this site, you agree to our Terms & Conditions.